Your shopping cart is currently empty

c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent. |
| In vitro | c-Met-IN-23 inhibits HGF-induced cell proliferation with IC 50 values of 12.4, 3.06, 19.30, and 16.85 µM for HT29, HepG2, MCF7, and MDA-MB-231 cells, respectively. At concentrations between 0.3 and 150 µM for 30 minutes, c-Met-IN-23 can block P-gp and MRP1/2 pumps in HepG2 and BxPC3 cells. Additionally, a concentration of 3 µM for 24 hours increases the expression of P-gp in HepG2 and BxPC3 cells and the expression of MRP1 and MRP2 in BxPC3 cells, while inhibiting P-gp-mediated efflux in HepG2 cells. |
| Formula | C16H13N7O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.